Asia-Pacific Lung Cancer Diagnostics Market to 2032

Overview

The Asia-Pacific Lung Cancer Diagnostics Market is expected to reach a 2,022.91 USD Billion by 2032 and is projected to grow at a CAGR of 23.12% from 2025 to 2032.

Revenue, 2024 (USD Billion)

603.97

Forecast, 2032 (USD Billion)

2,022.91

CAGR, 2024 - 2032

23.12%

Report Coverage

Asia-Pacific

Asia-Pacific Lung Cancer Diagnostics Market 2018-2032 USD Billion

Asia-Pacific Lung Cancer Diagnostics Market, Key Findings (2025-2032)

Market Growth and Projections:

Market Size (2024): 603.97 USD Billion
Projected Market Size (2032): 2,022.91 USD Billion
CAGR (2025-2032): 23.12%

Key Findings of Asia-Pacific Lung Cancer Diagnostics Market

The Asia-Pacific Lung Cancer Diagnostics Market was valued at 603.97 USD Billion in 2024.
The Asia-Pacific Lung Cancer Diagnostics Market is likely to grow at a CAGR of 23.12% during the forecast period of 2024 to 2032.
In 2024, the Largest segment Non-Small Cell Lung Cancer in Cancer Segment accounted for the largest share of the market with a revenue of 464.18 USD Billion
The fastest growing segment Hospital in End User Segment grew Fastest with a CAGR of 25.50% during the forecast period from 2024 to 2032.

Asia-Pacific Lung Cancer Diagnostics Market Scope

Asia-Pacific Lung Cancer Diagnostics Market Segmentation & Scope

Distribution Channel

Retail Sales
Direct Tender

End User

Others
Cancer Research Institutes
Diagnostic Imaging Centers
Independent Diagnostic Laboratories
Associated Labs
Hospital

Cancer

Small Cell Lung Cancer
Non-Small Cell Lung Cancer

Test

Others
Blood Test
Biopsy
Biomarkers Test
Imaging Test

Product

Consumables & Accessories
Instruments

Asia-Pacific Lung Cancer Diagnostics Market Data Coverage Insights

Study Period	2024-2032
Base Year	2021
Unit	Revenue in USD Billion
Market Value in 2024	603.97 USD Billion
Market Value in 2032	2,022.91 USD Billion
CAGR (2025-2032)	23.12%
Historic Data	2016-2023
Market Segments Covered	Distribution Channel,End User,Cancer,Test,Product

Regional Insights:

Leading Market (2024-2032): Asia-Pacific, leading in terms of revenue 603.97 USD Billion in 2024
- Key Country: China, leading in terms of revenue with value of 143.22 USD Billion in 2024.

Segments and Scope

Asia-Pacific Lung Cancer Diagnostics Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a revenue of 336.84 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a Growth rate of 24.40 % in forecast period 2025-2032.
Asia-Pacific Lung Cancer Diagnostics Market to 2032, By End User
- Hospital is the largest segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a revenue of 159.46 USD Billion in the year 2024.
- Hospital is the Fastest growing segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a Growth rate of 25.50 % in forecast period 2025-2032.
Asia-Pacific Lung Cancer Diagnostics Market to 2032, By Cancer
- Non-Small Cell Lung Cancer is the largest segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a revenue of 464.18 USD Billion in the year 2024.
- Non-Small Cell Lung Cancer is the Fastest growing segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a Growth rate of 23.35 % in forecast period 2025-2032.
Asia-Pacific Lung Cancer Diagnostics Market to 2032, By Test
- Imaging Test is the largest segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a revenue of 296.96 USD Billion in the year 2024.
- Imaging Test is the Fastest growing segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a Growth rate of 24.22 % in forecast period 2025-2032.
Asia-Pacific Lung Cancer Diagnostics Market to 2032, By Product
- Instruments is the largest segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a revenue of 384.22 USD Billion in the year 2024.
- Instruments is the Fastest growing segment in Asia-Pacific Lung Cancer Diagnostics Market to 2032 with a Growth rate of 24.04 % in forecast period 2025-2032.

Asia-Pacific Lung Cancer Diagnostics Market Company Share Analysis

Company Name
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Bio-Rad Laboratories, Inc.
Abbott
Guardant Health

Asia-Pacific Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion

Asia-Pacific Lung Cancer Diagnostics Market Company Profiling

Industry Related Reports

South America Hospital Furniture Market

Middle East & Africa Hospital Furniture Market

North America Hospital Furniture Market

Europe Hospital Furniture Market

Asia-Pacific Hospital Furniture Market

Argentina Hospital Furniture Market

Australia Hospital Furniture Market

Belgium Hospital Furniture Market

Brazil Hospital Furniture Market

Canada Hospital Furniture Market

Frequently Asked Questions

What are the primary segments covered in the Asia-Pacific Lung Cancer Diagnostics Market?

The Asia-Pacific Lung Cancer Diagnostics Market is segmented based on Segmentation Distribution Channel,End User,Cancer,Test,Product.

What is the current market size of the Asia-Pacific Lung Cancer Diagnostics Market?

Asia-Pacific Lung Cancer Diagnostics Market was valued at USD 603.97(Revenue in USD Billion) in 2021.

What is the expected growth rate of the Asia-Pacific Lung Cancer Diagnostics Market?

Asia-Pacific Lung Cancer Diagnostics Market is projected to grow at a CAGR of 23.12% during the forecast period of 2024 to 2032.

Which is the dominating segment in the Asia-Pacific Lung Cancer Diagnostics Market?

The Non-Small Cell Lung Cancer segment is expected to dominate the Asia-Pacific Lung Cancer Diagnostics Market, holding a largest market share of 464.18 USD Billion in 2024